Skip to main content

Peer Review reports

From: Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

Original Submission
28 Jul 2022 Submitted Original manuscript
22 Oct 2022 Reviewed Reviewer Report - Jiadi Gan
25 Oct 2022 Reviewed Reviewer Report
2 Nov 2022 Reviewed Reviewer Report - Waleed Kian
15 Nov 2022 Author responded Author comments - Satoru Miura
Resubmission - Version 2
15 Nov 2022 Submitted Manuscript version 2
22 Nov 2022 Author responded Author comments - Satoru Miura
Resubmission - Version 3
22 Nov 2022 Submitted Manuscript version 3
8 Dec 2022 Author responded Author comments - Satoru Miura
Resubmission - Version 4
8 Dec 2022 Submitted Manuscript version 4
15 Dec 2022 Reviewed Reviewer Report - Waleed Kian
18 Dec 2022 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
21 Dec 2022 Editorially accepted
3 Jan 2023 Article published 10.1186/s12885-022-10467-w

You can find further information about peer review here.

Back to article page